Premium
Long‐Term Results of a Phase III Randomized Trial of Postoperative Radiotherapy With or Without Carboplatin in Patients With High‐Risk Head and Neck Cancer
Author(s) -
Argiris Athanassios,
Karamouzis Michalis V.,
Johnson Jonas T.,
Heron Dwight E.,
Myers Eugene,
Eibling David,
Cano Elmer,
Urba Susan,
Gluckman Jack,
Grandis Jennifer R.,
Wang Yun,
Agarwala Sanjiv S.
Publication year - 2008
Publication title -
the laryngoscope
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.181
H-Index - 148
eISSN - 1531-4995
pISSN - 0023-852X
DOI - 10.1097/mlg.0b013e31815b48f4
Subject(s) - medicine , carboplatin , radiation therapy , randomized controlled trial , clinical endpoint , surgery , head and neck cancer , stage (stratigraphy) , chemotherapy , cisplatin , paleontology , biology
Background: The role of postoperative radiotherapy and carboplatin in squamous cell carcinoma of the head and neck (SCCHN) has not been established. Methods: Patients with macroscopically resected stage III/IV SCCHN with high‐risk pathologic features (≥3 lymph nodes, extracapsular extension, perineural or angiolymphatic invasion, or involved margins) were randomized to receive postoperative radiotherapy alone (arm A) or the same radiotherapy plus carboplatin 100 mg/m 2 intravenously once weekly during radiation (arm B). The primary endpoint was 2‐year disease‐free survival. Results: Seventy‐six patients were randomized, of whom 72 were eligible and analyzable (36 in each arm). The study was prematurely closed because of slow accrual. With a median follow‐up of 5.3 years, the disease‐free survival at 2 and 5 years was 71% and 53% in arm B versus 58% ( P = .27) and 49% ( P = .72) in arm A. The overall survival at 2 and 5 years was 74% and 47% in arm B versus 51% ( P = .04) and 41% ( P = .61) in arm A. Serious toxicities were infrequent in both arms. Conclusions: We could not demonstrate a benefit with the addition of carboplatin to postoperative radiotherapy, possibly because of insufficient sample size.